United StatesA U.S. appeals court has revived a lawsuit filed by Teva Pharmaceuticals against Eli Lilly, alleging that Lilly violated an agreement allowing Teva to market a generic version of Lilly's osteoporosis drug Forteo. The court overturned a previous ruling that had determined the agreement had expired before Lilly allegedly breached it. The dispute dates back to 2016, when Lilly sued Teva for patent infringement, leading to a 2018 settlement that permitted Teva to launch its generic drug in 2019. However, Lilly secured additional FDA exclusivity in 2020, which Teva claims unlawfully delayed its launch. Separately, a major clinical trial called PROTECT-Cog has begun, aiming to investigate whether lifestyle modifications combined with GLP-1 agonists or similar treatments can reduce the risk of dementia. Funded with $100 million, the three-year study will examine the effects of different lifestyle interventions—both intensive and less strict—with and without medication, focusing on older adults at higher risk of cognitive decline.
Bias read (Center): The article presents a factual overview of legal disputes between pharmaceutical companies and discusses a medical research initiative. It does not exhibit clear ideological bias, as it reports on legal proceedings and scientific research without overtly favoring one side over the other. The framing
